What type of study is this?

This is a Pre-Registered Trial study.

Safety and efficacy of stapokibart, an anti–IL-4Rα monoclonal antibody, in children aged 6–11 years with moderate-to-severe atopic dermatitis: An open-label, single-arm phase 1b/2a trial

View Full Paper

Ask AI

Bookmark

Stapokibart improved disease outcomes, with 68% reporting mild or moderate adverse events.
At week 8, 75% of children aged 15–30 kg achieved EASI-75, indicating significant efficacy.
Patients received stapokibart based on body weight, with a total of three to four doses over eight weeks.
Findings highlight potential benefits of stapokibart for treating moderate-to-severe atopic dermatitis in children.

No takes yet. Share an insight, caveat, or question.

Open-label trial demonstrates stapokibart improves AD symptoms in children with 75% achieving EASI-75, suggesting its promise for treatment.

Zhao et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Open-label trial demonstrates stapokibart improves AD symptoms in children with 75% achieving EASI-75, suggesting its promise for treatment.